CONTRAINDICATIONS

  • INCRUSE ELLIPTA is contraindicated in patients with severe hypersensitivity to milk proteins or with hypersensitivity to umeclidinium or any of the excipients.

...continue reading

INDICATION

INCRUSE ELLIPTA is an anticholinergic indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

For the long-term, once-daily, maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD)

INDICATION

INCRUSE ELLIPTA is an anticholinergic indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

823654R0 July 2017